Back to All Collaborations

Neglected Tropical Disease Drug Discovery Booster

Active Since: 2015

Multi-Company Partnership

Contributing to SDGs…

This multi-company collaborative project with the Drugs for Neglected Diseases Initiative (DNDi) is focused on finding new treatments for leishmaniasis and Chagas disease.

PARTNER ORGANISATIONS

  • Global NGOs

    Drugs for Neglected Diseases initiative (DNDi)

Objectives

Accelerate the process and reduce the cost of finding new treatments for leishmaniasis and Chagas disease.

Leishmaniasis is a potentially fatal parasitic disease caused by various species of sandflies. The disease, which occurs in multiple forms, is prominent among the poorest people on earth and can result in malnutrition, population displacement and overall poor economic well-being of communities.

Chagas disease is primarily transmitted by large, blood-sucking insects widely known as “the kissing bugs” in endemic countries. In the initial, acute phase of disease, 5% of infected children die. The chronic phase of disease, which develops in 10-30% of infected individuals, can cause damage to the heart.  Current treatment lasts 8 weeks and many patients fail to complete the course. A shorter course therapy would help improve success rates for treatment.

In this collaboration, compound libraries from partner organizations are searched to find those with potential to treat these diseases. The process is both multilateral and iterative: partner companies continually examine their libraries for better matches as each search is refined. This significantly reduces the time it takes to find new, promising treatment leads and potentially reduces attrition.

SDGs THE PARTNERSHIP CONTRIBUTES TO

SDG 3: Good Health and Wellbeing

  1. 3.3: Communicable Diseases & NTDs

SDG 9: Industry Innovation and Infrastructure

SDG 17: Partnerships for the Goals 

RESULTS & MILESTONES

Since its creation in 2015, the Booster has gone through 45 iterations, generating 13 hit series, of which six have progressed to in vivo proof-of-concept studies for Chagas disease or leishmaniasis.